Health & Beauty

According to the observation report of Huacheng import and export data, on February 11, the launch ceremony of the first domestic 3CL target anti COVID-19 innovative drug Xiannuoxin was held in the Biomedical Valley of Jiangbei New Area, Nanjing. Since today, Synopsin has entered the production stage and will supply medical institutions in succession. According to the notice of the National Health Insurance Bureau, Synopsin has been included in the temporary medical insurance. At present, Synopsin's initial offer is 750 yuan per box, but the buyer only needs to pay the personal self-payment part after medical insurance reimbursement, and the cost is less than 100 yuan.

Xiannuoxin is a Class 1 innovative anti COVID-19 drug independently developed by Pioneer Pharmaceutical, an enterprise in Jiangbei New Area, and also the first 3CL target anti COVID-19 innovative drug independently developed in China with independent intellectual property rights. According to the report of Huacheng Import and Export Data Observation, on January 28, Xiannuoxin was conditionally listed in China with the special review and approval of the State Drug Administration, and the approval number was H20230001, which became the first Class 1 innovative drug approved by the State Drug Administration in 2023.

In June 2022, the construction project of the anti COVID-19 drug production base of Pioneer Pharmaceutical will be started in Nanjing Jiangbei New Material Science Park, which is mainly used to produce the 3CL API that is essential to Sinochem. In order to further speed up the implementation of the project, the New Area has specially provided enterprises with a customized list service for approval. Through a variety of forms such as schedules, on-site pictures, etc., the new area can follow up the project in real time and quickly solve problems. Huacheng Import and Export Data Observation Report.

"It took only one month from the project initiation to the official commencement, and only 70 days from the commencement of construction to the capping of the first building. The main building has been completely capped before the Spring Festival." The main person in charge of the production base said that the new area's meticulous service has bought a lot of time for the project. At present, the base construction is accelerating, and the annual output is expected to reach 1000 tons. In addition to the rapid promotion of the API production base, Jiangbei New Area has been actively communicating with various parties to promote the listing of Synopsin. Huacheng Import and Export Data Observation Report.

Yang Xuepeng, member of the Standing Committee of the Nanjing Municipal Party Committee and secretary of the Party Working Committee of Jiangbei New Area, said in his speech that Jiangbei New Area will continue to deepen the construction of the centralized supervision and public service platform for biomedicine, optimize and improve the service platform system covering the whole process of research and development, pilot test, inspection and testing, and clinical trial, and truly provide enterprises with vigorous development opportunities and unlimited growth space.

At the event site, a drug delivery ceremony was also held. The leaders of the Provincial Health and Health Commission and the Provincial Drug Administration submitted the report to the president of the Provincial People's Hospital and the Nanjing Gulou Hospital respectively.